SpringWorks Hopes Pediatric Plus Adult Data Make Mirdametinib Go-To For NF1-PN

 
• By Alaric DeArment

The company plans to file for FDA approval in the first half of 2024 as it eyes a market of about 40,000 adult and pediatric patients in the US.

SpringWorks announced data from its Phase IIb trial of mirdametinib in the rare disease NF1. • Source: Shutterstock

More from Clinical Trials

More from R&D